Log in to save to my catalogue

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8984092

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum

About this item

Full title

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum

Publisher

United States: John Wiley & Sons, Inc

Journal title

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2022, Vol.14 (1), p.e12307-n/a

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Introduction
We evaluated a new Simoa plasma assay for phosphorylated tau (P‐tau) at aa217 enhanced by additional p‐tau sites (p217+tau).
Methods
Plasma p217+tau levels were compared to 18F‐NAV4694 amyloid beta (Aβ) positron emission tomography (PET) and 18F‐MK6240 tau PET in 174 cognitively impaired (CI) and 223 cognitively unimpaired (CU...

Alternative Titles

Full title

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8984092

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8984092

Other Identifiers

ISSN

2352-8729

E-ISSN

2352-8729

DOI

10.1002/dad2.12307

How to access this item